Single step capture and assessment of multiple plasma extracellular vesicle biomarkers in Alzheimer's disease detection
Journal of Alzheimer’s Disease · 2024
DOI: 10.1177/13872877241291964 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Alzheimer’s Disease, 2024. Verfasst von Jean M Lewis und 9 weiteren Autor:innen. Beteiligte Einrichtung: Biological Dynamics, Inc., San Diego, CA, USA. Hauptthemen laut MEDLINE: Alzheimer Disease, Extracellular Vesicles, Biomarkers. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: Alzheimer's Drug Discovery Foundation, NIH.
Themen: Demenz
Abstract (Originalsprache)
Background
Blood tests for Alzheimer's disease (AD) that measure biomarkers related to neuropathology have demonstrated to be useful, minimally-invasive ways to identify patients for screening into clinical trials. While some AD biomarkers can be detected in plasma, greater sensitivity is needed to make plasma AD tests more effective. Extracellular vesicles (EVs) in plasma carry AD-related biomarkers from the brain and could offer a concentrated source of brain-related biomarkers, though the methodological complexities involved in isolating plasma EVs have hampered its validation for clinical use.
Objective
To explore the feasibility and effectiveness of developing blood tests for AD utilizing extracellular vesicle-bound protein biomarkers.
Methods
We developed a simplified method for isolating EVs directly from plasma using an alternating current electrokinetic (ACE) microchip. No sample pretreatment steps were needed. Protein biomarkers on the EVs were detected by adding fluorescent antibodies to the plasma samples before capture by the chip. This allowed measurement of EV biomarker levels directly on the chip.
Results
AD or non-AD control plasma was measured for ten different AD-related biomarkers. EV-associated NCAM1, pTau231, α-synuclein, and TDP-43 levels were able to distinguish a group of 10 AD, 10 mild cognitive impairment (MCI), and 10 non-AD subjects. pTau231 was different between AD and non-AD (p = 0.0300) and α-synuclein differentiated AD from MCI (p = 0.0148).
Conclusions
This study shows how ACE microfluidic chip technology can help differentiate AD and MCI patients from non-AD controls with clinical relevance. This work also highlights the important diagnostic role of plasma EV biomarkers in neurodegenerative disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Biological Dynamics, Inc., San Diego, CA, USA.
- Alzheimer's Therapeutic Research Institute, Keck School of Medicine of the University of Southern California, San Diego, CA, USA.
ORCID-Profile: Jean M Lewis, Dorathy-Ann Harris, Harmeet Dhani
Förderung
- Alzheimer's Drug Discovery Foundation
- NIH
Zitieren
APA
Lewis, J. M., Harris, D. A., Kosmatka, J., Mikrut, E., Evenson, J., Balcer, H. I., Dhani, H., Hinestrosa, J. P., Rissman, R., & Billings, P. R. (2024). Single step capture and assessment of multiple plasma extracellular vesicle biomarkers in Alzheimer's disease detection. Journal of Alzheimer’s Disease. https://doi.org/10.1177/13872877241291964
Vancouver
Lewis JM, Harris DA, Kosmatka J, Mikrut E, Evenson J, Balcer HI, et al. Single step capture and assessment of multiple plasma extracellular vesicle biomarkers in Alzheimer's disease detection. Journal of Alzheimer’s Disease. 2024. doi:10.1177/13872877241291964
BibTeX
@article{Lewis2024,
author = {Lewis, Jean M and Harris, Dorathy-Ann and Kosmatka, Janell and Mikrut, Emily and Evenson, Jack and Balcer, Heath I and Dhani, Harmeet and Hinestrosa, Juan Pablo and Rissman, Robert and Billings, Paul R},
title = {Single step capture and assessment of multiple plasma extracellular vesicle biomarkers in Alzheimer's disease detection},
journal = {Journal of Alzheimer’s Disease},
year = {2024},
doi = {10.1177/13872877241291964}
}
EUVIMED